Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 13Sarcoma, Myeloid 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Promyelocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 32Vincristine 22blinatumomab 20Methotrexate 20Specimen Handling 19Prednisone 19Cytarabine 17merphos 16prednylidene 15deltacortene 15Biopsy 15Mercaptopurine 14Doxorubicin 14Dexamethasone 14N,N-dicyclohexyl-isoborneol-10-sulfonamide 13pegaspargase 12azathiopurine 12Rituximab 12Etoposide 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11Spinal Puncture 11Calcium Dobesilate 11Asparaginase 11Leucovorin 10fludarabine 9Magnetic Resonance Spectroscopy 9Inotuzumab Ozogamicin 9Daunorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Mitoxantrone × 90 days × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡